Profile data is unavailable for this security.
About the company
InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The Company focuses on areas with large unmet clinical needs, such as oncology and autoimmune diseases. The Company's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The Company is also developing products for the treatment of autoimmune diseases caused by abnormal B cell or T cell function. The Company mainly conducts its businesses in domestic and overseas markets.
- Revenue in HKD (TTM)796.72m
- Net income in HKD-681.00m
- Incorporated2015
- Employees1.09k
- LocationInnoCare Pharma LtdBuilding 8, No. 8Life Science Park Road, ZhongguancunLife Science Park, Changping DistrictBeijing 102206ChinaCHN
- Phone+86 1 066609999
- Fax+86 1 060702992
- Websitehttps://www.innocarepharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tong Ren Tang Technologies Co Ltd | 7.31bn | 636.69m | 7.21bn | 4.10k | 11.33 | 0.9702 | 5.27 | 0.9868 | 0.4971 | 0.4971 | 5.71 | 5.80 | 0.5212 | 0.9835 | 5.68 | 1,781,785.00 | 7.64 | 7.68 | 12.10 | 12.32 | 42.04 | 43.50 | 14.65 | 16.11 | 2.37 | -- | 0.1443 | 39.94 | 13.04 | 6.01 | 1.25 | -2.73 | -22.26 | 0.0178 |
China Shineway Pharmaceutical Group Ltd | 4.87bn | 1.05bn | 7.56bn | 3.44k | 6.60 | 0.996 | 6.17 | 1.55 | 1.38 | 1.38 | 6.45 | 9.18 | 0.5073 | 1.44 | 6.31 | 1,418,035.00 | 10.89 | 8.03 | 14.15 | 9.77 | 75.15 | 74.55 | 21.47 | 17.87 | 2.98 | -- | 0.0411 | 36.29 | 14.32 | 11.94 | 34.14 | 13.89 | 0.6396 | 12.88 |
Beijing Tong Ren Tang Chinese Medicine | 1.52bn | 540.39m | 8.10bn | 798.00 | 14.99 | 2.10 | 12.04 | 5.31 | 0.6456 | 0.6456 | 1.82 | 4.62 | 0.3522 | 0.6449 | 2.31 | 1,910,959.00 | 13.64 | 16.71 | 15.50 | 18.75 | 68.67 | 69.88 | 38.73 | 40.72 | 8.59 | -- | 0.0317 | 68.87 | -11.91 | 0.1459 | -16.33 | -1.43 | -16.30 | 7.49 |
Everest Medicines Ltd | 135.85m | -910.99m | 8.28bn | 432.00 | -- | 1.52 | -- | 60.97 | -2.91 | -2.91 | 0.434 | 16.78 | 0.0203 | 2.25 | 4.57 | 314,475.40 | -13.63 | -30.52 | -15.06 | -33.14 | 72.67 | -- | -670.57 | -5,745.25 | 8.29 | -- | 0.0979 | -- | 884.46 | -- | -241.50 | -- | 4.65 | -- |
Shanghai Henlius Biotech Inc | 5.82bn | 589.04m | 9.03bn | 3.64k | 15.38 | 3.82 | 9.25 | 1.55 | 1.08 | 1.08 | 10.66 | 4.35 | 0.5731 | 1.95 | 9.10 | 1,600,203.00 | 5.80 | -8.59 | 12.47 | -14.14 | 72.64 | 71.77 | 10.12 | -27.37 | 0.3786 | 6.48 | 0.6512 | -- | 67.82 | 273.51 | 178.53 | -- | 49.14 | -- |
Cansino Biologics Inc | 372.38m | -1.60bn | 9.41bn | 1.49k | -- | 0.9096 | -- | 25.27 | -6.48 | -6.48 | 1.51 | 23.03 | 0.0332 | 2.37 | 0.4619 | 249,248.10 | -18.93 | -4.27 | -26.69 | -5.60 | -253.78 | -- | -569.97 | -27.72 | 1.86 | -- | 0.3381 | -- | -66.52 | 213.94 | -63.04 | -- | 30.60 | -- |
Lepu Biopharma Co Ltd | 243.11m | -23.84m | 9.46bn | 429.00 | -- | 9.78 | 121.57 | 38.91 | -0.0144 | -0.0144 | 0.1465 | 0.5831 | 0.0917 | 1.06 | 1.62 | 566,680.70 | -1.23 | -- | -1.91 | -- | 87.45 | -- | -13.45 | -- | 0.7201 | 0.1388 | 0.4549 | -- | 1,347.16 | -- | 96.79 | -- | -- | -- |
Keymed Biosciences Inc | 381.99m | -387.67m | 10.07bn | 897.00 | -- | 3.13 | -- | 26.36 | -1.49 | -1.49 | 1.45 | 11.52 | 0.0906 | 0.7314 | 26.14 | 425,854.90 | -9.16 | -- | -10.05 | -- | 89.59 | -- | -101.04 | -- | 9.18 | -- | 0.123 | -- | 253.87 | -- | -16.63 | -- | -- | -- |
InnoCare Pharma Ltd | 796.72m | -681.00m | 10.23bn | 1.09k | -- | 1.17 | -- | 12.84 | -0.4038 | -0.4038 | 0.4721 | 4.37 | 0.073 | 1.39 | 3.39 | 731,608.40 | -6.38 | -13.41 | -8.08 | -15.36 | 82.61 | 85.99 | -87.42 | -172.16 | 4.13 | -- | 0.1582 | -- | 18.09 | 240.36 | 28.80 | -- | 66.20 | -- |
AIM Vaccine Co Ltd | 1.28bn | -1.40bn | 10.35bn | 1.62k | -- | 2.63 | -- | 8.08 | -1.16 | -1.16 | 1.06 | 3.24 | -- | -- | -- | 788,805.90 | -- | -- | -- | -- | 75.88 | -- | -164.24 | -- | 0.7583 | -14.04 | 0.3158 | -- | -6.06 | -- | -307.07 | -- | -- | -- |
Yichang Hec Changjiang Pharmactcl Co Ltd | 6.79bn | 2.15bn | 11.14bn | 4.62k | 5.18 | 1.30 | 4.59 | 1.64 | 2.44 | 2.44 | 7.72 | 9.73 | 0.5111 | 3.62 | 4.09 | 1,470,441.00 | 15.07 | 8.03 | 24.46 | 11.81 | 79.21 | 79.97 | 29.48 | 20.80 | 1.30 | 11.16 | 0.2475 | 15.81 | 68.08 | 20.18 | 2,501.24 | 16.15 | -11.50 | -- |
Luye Pharma Group Ltd | 6.63bn | 574.57m | 11.25bn | 5.27k | 19.48 | 0.832 | 8.40 | 1.70 | 0.1535 | 0.1535 | 1.78 | 3.59 | 0.247 | 2.42 | 3.60 | 1,257,505.00 | 2.17 | 2.80 | 3.56 | 4.45 | 68.44 | 70.53 | 8.78 | 10.39 | 1.21 | 3.10 | 0.3931 | 11.82 | 2.70 | 3.50 | -11.94 | -16.39 | -14.05 | -- |
SciClone Pharmaceuticals (Holdings) Ltd | 3.40bn | 1.21bn | 11.34bn | 1.05k | 9.72 | 3.21 | 14.84 | 3.33 | 1.86 | 1.86 | 5.23 | 5.62 | 0.7585 | 3.56 | 3.83 | 3,242,118.00 | 26.97 | 27.09 | 33.34 | 36.32 | 74.67 | 76.06 | 35.55 | 35.43 | 4.50 | 27.95 | 0.01 | -- | 14.76 | 17.50 | 31.16 | 15.96 | -- | -- |
Zai Lab Ltd | 2.08bn | -2.61bn | 13.14bn | 2.18k | -- | 2.07 | -- | 6.31 | -2.70 | -2.70 | 2.16 | 6.40 | 0.2364 | 2.51 | 5.38 | -- | -29.66 | -37.72 | -34.97 | -42.72 | 64.08 | 64.75 | -125.46 | -282.44 | 4.41 | -- | 0.00 | -- | 24.03 | 360.03 | 24.51 | -- | -3.45 | -- |
Holder | Shares | % Held |
---|---|---|
HHLR Advisors Ltd.as of 30 Jun 2023 | 208.67m | 13.93% |
GIC Pte Ltd. (Investment Management)as of 11 Apr 2024 | 35.15m | 2.35% |
The Vanguard Group, Inc.as of 05 Apr 2024 | 27.89m | 1.86% |
E Fund Management Co., Ltd.as of 30 Jun 2023 | 16.62m | 1.11% |
Norges Bank Investment Managementas of 31 Dec 2023 | 8.99m | 0.60% |
Bosera Asset Management Co., Ltd.as of 31 Dec 2022 | 8.18m | 0.55% |
RBC Global Asset Management (UK) Ltd.as of 29 Feb 2024 | 6.13m | 0.41% |
BlackRock Fund Advisorsas of 04 Apr 2024 | 5.30m | 0.35% |
FIL Investment Management (Hong Kong) Ltd.as of 31 Mar 2024 | 5.21m | 0.35% |
Dimensional Fund Advisors LPas of 04 Apr 2024 | 4.42m | 0.30% |